The new political economy of pharmaceuticals : production, innnovation and trips in the global south / edited by Hans Löfgren, associate professor, School of Humanities and Social Sciences, Deakin University, Australia and Owain David Williams, research fellow, Centre for Health and International Relations, Aberystwyth University, UK
1. The new political economy of pharmaceuticals: conformity and resistance in the global South; owain David Williams and Hans Ḻfgren -- 2. The political economy of pharmaceutical production in Brazil; Cassandra M. Sweet -- 3. Pharmaceuticals, health policy and intellectual property rights in China; Chee-Ruey Hsieh -- 4. Immunity to TRIPS? vaccine production and the Biotechnology Industry in Cuba; Jens Plahte and Simon Reid-Henry -- 5. TRIPS and access to medicines in Egypt; Dina Iskander -- 6. The pharmaceutical industry in India after TRIPS; Sudip Chaudhuri -- 7. The health care system and the pharmaceutical industry in Indonesia; Richard Husada and Raymond R. Tjandrawinata -- 8. TRIPS, Free Trade Agreements and the pharmaceutical industry in Malaysia; Mohamed Azmi Hassali, Jayabalan Thambyappa, Shankaran Nambiar and Asrul Akmal Shafie -- 9. The pharmaceutical industry, intellectual property rights and access to medicines in Pakistan: Zaheer-Ud-Din Babar, Shazia Jamshed, Ashar Malik and Anwarul-Hassan Gilani -- 10. TRIPS, access to medicines and local production in South Africa; Andrew L. Gray and Yousuf A. Vawda -- 11. TRIPS and new challenges for the pharmaceutical sector in South Korea; Bong-min Yang and Hye-young Kwon -- 12. Intellectual property rights and neoliberal restructuring in Turkey: the pharmaceutical Industry; Ipek Eren Vural -- 13. Conclusion: TRIPS, drug production in the Global South, and access to medicines; Hans Ḻfgren and Owain David Williams
Summary
"Some two decades will shortly have passed since the WTO's Trade Related Aspects of Intellectual Property Rights agreement came into force in 1995. TRIPS is widely considered to have had a negative impact on access to medicines through its rules on pharmaceutical patents. This volume is the first cross-country analysis of how TRIPS has affected the capacity of 11 major low or medium income countries to produce generic drugs and assesses the wider political economy of drug production and consumption in the Global South"-- Provided by publisher
